MX2016007930A - Formulaciones orales de derivados de pirrolidina. - Google Patents

Formulaciones orales de derivados de pirrolidina.

Info

Publication number
MX2016007930A
MX2016007930A MX2016007930A MX2016007930A MX2016007930A MX 2016007930 A MX2016007930 A MX 2016007930A MX 2016007930 A MX2016007930 A MX 2016007930A MX 2016007930 A MX2016007930 A MX 2016007930A MX 2016007930 A MX2016007930 A MX 2016007930A
Authority
MX
Mexico
Prior art keywords
oral formulations
pyrrolidine derivatives
present
formulations
methyloxime
Prior art date
Application number
MX2016007930A
Other languages
English (en)
Other versions
MX363697B (es
Inventor
Chollet Andre
Pohl Oliver
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MX2016007930A publication Critical patent/MX2016007930A/es
Publication of MX363697B publication Critical patent/MX363697B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)

Abstract

La presente invención se refiere a formulaciones orales sólidas que comprenden un compuesto de la fórmula O-metiloxima de (3Z,5S)-5-(hidroximetil)-1-[(2'-metil- 1,1 '-bifenil-4-il)carbonil ]pirrolidin-3-ona, y/o un metabolito activo del mismo, y al uso de dichas formulaciones en el tratamiento y/o prevención de parto prematuro, nacimiento prematuro, dismenorrea y fracaso de implantación del embrión debido a contracciones uterinas. La presente invención se refiere además a procedimientos para su preparación.
MX2016007930A 2013-12-17 2014-12-15 Formulaciones orales de derivados de pirrolidina. MX363697B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197606.0A EP2886107A1 (en) 2013-12-17 2013-12-17 Oral formulations of pyrrolydine derivatives
PCT/EP2014/077767 WO2015091365A1 (en) 2013-12-17 2014-12-15 Oral formulations of pyrrolidine derivatives

Publications (2)

Publication Number Publication Date
MX2016007930A true MX2016007930A (es) 2016-09-19
MX363697B MX363697B (es) 2019-03-29

Family

ID=49765403

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007930A MX363697B (es) 2013-12-17 2014-12-15 Formulaciones orales de derivados de pirrolidina.
MX2019003598A MX2019003598A (es) 2013-12-17 2016-06-16 Formulaciones orales de derivados de pirrolidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019003598A MX2019003598A (es) 2013-12-17 2016-06-16 Formulaciones orales de derivados de pirrolidina.

Country Status (19)

Country Link
US (5) US20170065556A1 (es)
EP (4) EP2886107A1 (es)
JP (2) JP6479800B2 (es)
KR (1) KR102350156B1 (es)
CN (2) CN110960495B (es)
AU (1) AU2014364962B2 (es)
CA (1) CA2931592C (es)
CY (1) CY1119728T1 (es)
DK (1) DK3082773T3 (es)
EA (2) EA031530B1 (es)
ES (2) ES2654927T3 (es)
HK (1) HK1249050B (es)
HU (1) HUE035212T2 (es)
IL (2) IL245855B (es)
MX (2) MX363697B (es)
PT (1) PT3082773T (es)
SI (1) SI3082773T1 (es)
UA (1) UA116824C2 (es)
WO (1) WO2015091365A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CA2953722C (en) 2014-07-02 2022-09-13 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021043726A1 (en) * 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
ES2929818T3 (es) 2020-05-18 2022-12-02 Orexo Ab Nueva composición farmacéutica para la administración de fármacos
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482815A (en) 1967-07-07 1969-12-09 Victor Naturale Collapsible core for a mold
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US4832307A (en) 1988-09-15 1989-05-23 Toshiba Kikai Kabushiki Kaisha Injection mold
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
JP2927532B2 (ja) 1989-11-09 1999-07-28 塩野義製薬株式会社 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP2869854B2 (ja) 1994-10-19 1999-03-10 株式会社トスカ 合成樹脂の成形方法とその装置
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SK285706B6 (sk) * 1999-12-09 2007-06-07 Reckitt Benckiser Healthcare (Uk) Limited Lisovaná tabletová kompozícia, spôsob jej prípravy a jej použitie
AU5620901A (en) 2000-03-27 2001-10-08 Applied Research Systems Pharmaceutically active pyrrolidine derivatives as bax inhibitors
EP1268418B1 (en) 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
EP1390347B1 (en) 2001-03-20 2008-05-07 Laboratoires Serono SA Pyrrolidine ester derivatives with oxytocin modulating activity
SK15552003A3 (sk) 2001-06-18 2004-05-04 Applied Research Systems Ars Holding N. V. Oxadiazolové a tiadiazolové deriváty pyrolidínu, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
JP2003192582A (ja) * 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
JP4773335B2 (ja) * 2003-02-27 2011-09-14 メルク セローノ ソシエテ アノニム オキシトシンアンタゴニストとしてのピロリジン誘導体
KR20060124775A (ko) 2004-02-26 2006-12-05 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 피롤리딘 옥심의 제조방법
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
RU2385735C2 (ru) * 2005-05-10 2010-04-10 Ферринг Интернэшнл Сентер С.А. Применение антагонистов окситоцина при вспомогательной репродукции
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
WO2007074472A2 (en) * 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
US20090152770A1 (en) 2007-08-07 2009-06-18 Canon Virginia Inc. Mechanically collapsible core for injection molding
PL2572705T3 (pl) * 2007-10-01 2018-01-31 Lesvi Laboratorios Sl Tabletki ulegające rozpadowi w jamie ustnej
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
JP5942815B2 (ja) 2012-11-26 2016-06-29 株式会社ジェイテクト 等速ジョイント用ブーツの成形金型
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CA2953722C (en) 2014-07-02 2022-09-13 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Also Published As

Publication number Publication date
PT3082773T (pt) 2018-01-09
EP3266449B1 (en) 2019-02-27
US11419851B2 (en) 2022-08-23
CN110960495A (zh) 2020-04-07
MX2019003598A (es) 2019-07-15
EA201691061A1 (ru) 2016-11-30
EP3494967A1 (en) 2019-06-12
CN110960495B (zh) 2022-05-10
EA031530B1 (ru) 2019-01-31
IL264259A (en) 2019-02-28
ES2726730T3 (es) 2019-10-08
WO2015091365A1 (en) 2015-06-25
UA116824C2 (uk) 2018-05-10
CN106029057B (zh) 2019-09-03
HUE035212T2 (en) 2018-05-02
EA201892033A3 (ru) 2019-03-29
IL245855B (en) 2019-02-28
EP3082773A1 (en) 2016-10-26
KR20160097359A (ko) 2016-08-17
DK3082773T3 (en) 2018-01-08
CA2931592C (en) 2021-12-07
AU2014364962A1 (en) 2016-07-28
JP2019108336A (ja) 2019-07-04
CA2931592A1 (en) 2015-06-25
US20170065556A1 (en) 2017-03-09
AU2014364962B2 (en) 2020-03-26
CN106029057A (zh) 2016-10-12
US20180311211A1 (en) 2018-11-01
SI3082773T1 (en) 2018-02-28
US10478420B2 (en) 2019-11-19
CY1119728T1 (el) 2018-06-27
US20200281892A1 (en) 2020-09-10
JP6479800B2 (ja) 2019-03-06
US20150164859A1 (en) 2015-06-18
EP3266449A1 (en) 2018-01-10
EA201892033A2 (ru) 2019-02-28
MX363697B (es) 2019-03-29
EP3082773B1 (en) 2017-10-04
HK1249050B (zh) 2020-01-17
US20230226021A1 (en) 2023-07-20
EP2886107A1 (en) 2015-06-24
JP2016540758A (ja) 2016-12-28
ES2654927T3 (es) 2018-02-15
KR102350156B1 (ko) 2022-01-11
US9962367B2 (en) 2018-05-08
IL245855A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
MX2016007930A (es) Formulaciones orales de derivados de pirrolidina.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA027953B9 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
EA201170922A1 (ru) Производные сульфонамида
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
EA201891873A1 (ru) Кристаллический о-метилоксим (3z,5s)-5-(гидроксиметил)-1-[(2'-метил-1,1'-бифенил-4-ил)карбонил]пирролидин-3-он, полезный в способах лечения состояний, связанных с активностью ot-r
PH12015500823A1 (en) Modified release formulations for oprozomib
UA117154C2 (uk) Антагоністи s1p3
TR201902057T4 (tr) Tetrasiklin bileşikleri.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
PH12015502326A1 (en) Progesterone receptor antagonist dosage form
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
NZ801872A (en) Managing moderate to severe pain associated with endometriosis in patients classified as child-pugh b
AR117298A1 (es) Aglutinante de péptido
MX354999B (es) Composicion con un inhibidor de la bomba de protones y un antagonista h2.
MX2016017312A (es) Composición farmacéutica de solifenacina en una tableta por comprension directa para su administración oral, para el tratamiento de alopatías relacionadas al mal funcionamiento de la vejiga.
RU2013125868A (ru) Способ хирургического лечения гастроэзофагеальной рефлюксной болезни
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids